Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...
US FDA declines full approval for Intercept's liver disease drug
The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...
Business Insider20h
Eupraxia reports data from RESOLVE Phase 1b/2a trial
Eupraxia Pharmaceuticals (EPRX)announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic ...
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the third quarter 2024 and provided a business update. "The Mirum team executed ...
Business Insider22h
Sanofi treatment of acute myeloid leukemia granted orphan status
A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...